-
公开(公告)号:US11530179B2
公开(公告)日:2022-12-20
申请号:US17079129
申请日:2020-10-23
申请人: Geron Corporation
IPC分类号: C07C235/00 , C07C231/12
摘要: Aspects of the disclosure includes methods for preparing an amorphous solid composition of a fatty acid metal salt. In practicing the subject methods according to certain embodiments, a succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane organic salt is contacted with a metal base to produce a succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt; and the succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt is precipitated in a solvent to produce an amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition. An amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane lithium salt is also provided.
-
公开(公告)号:US20220168333A1
公开(公告)日:2022-06-02
申请号:US17670278
申请日:2022-02-11
申请人: Geron Corporation
发明人: Fei Huang , Joshua J. Rusbuldt , Aleksandra Rizo
IPC分类号: A61K31/7125 , A61K31/635 , A61K45/06 , A61K31/496
摘要: The present invention relates to a combination treatment for hematological cancers. More specifically; a combination of a telomerase inhibitor and a Bcl-2 inhibitor are useful in treating hematological cancers, including AML. In certain embodiments, the telomerase inhibitor is imetelstat or imetelstat sodium and the Bcl-2 inhibitor is ABT-199.
-
公开(公告)号:US11279720B2
公开(公告)日:2022-03-22
申请号:US16784825
申请日:2020-02-07
申请人: Geron Corporation
IPC分类号: C07F9/6561 , C07D473/18
摘要: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
-
54.
公开(公告)号:US20210269807A1
公开(公告)日:2021-09-02
申请号:US17088303
申请日:2020-11-03
申请人: Geron Corporation
发明人: Xiaoli Wang , Fei Huang
IPC分类号: C12N15/113 , A61K31/519 , A61K31/506 , A61K31/5377 , A61K31/529
摘要: Aspects of the disclosure include methods for treating a myeloproliferative neoplasm. Methods according to certain embodiments include co-administering to a subject a Janus kinase (JAK) inhibitor and a telomerase inhibitor comprising an oligonucleotide and a lipid moiety linked to the 5′ and/or 3′ end of the oligonucleotide. Methods for inducing apoptosis of a myeloproliferative neoplasm cell by contacting the cell with an amount of a JAK inhibitor and a telomerase inhibitor sufficient to induce apoptosis are also described. Compositions having a JAK inhibitor and a telomerase inhibitor for practicing the subject methods are also provided.
-
公开(公告)号:US20200339975A1
公开(公告)日:2020-10-29
申请号:US16926340
申请日:2020-07-10
申请人: Geron Corporation
IPC分类号: C12N15/10 , C12N15/113
摘要: Aspects of the disclosure include methods for the preparation of a polynucleotide. In some embodiments, the method includes contacting a first polynucleotide composition including: a polynucleotide having a sequence of 7 or more nucleoside subunits and at least two of the nucleoside subunits are joined by a N3′→P5′ thiophosphoramidate inter-subunit linkage; and non-target synthetic products and reagents; with a multivalent cation salt to precipitate a polynucleotide salt including at least one multivalent cation counterion; and separating the polynucleotide salt from the contacted first polynucleotide composition to produce a second polynucleotide composition including the polynucleotide salt. In certain embodiments, the method further includes contacting the polynucleotide salt with a reverse phase chromatography support; and eluting from the chromatography support a third polynucleotide composition including the polynucleotide. Also provided are compositions including a salt of the polynucleotide including at least one multivalent cation counterion.
-
公开(公告)号:US20200283461A1
公开(公告)日:2020-09-10
申请号:US16784825
申请日:2020-02-07
申请人: Geron Corporation
IPC分类号: C07F9/6561 , C07D473/18
摘要: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
-
公开(公告)号:US10745687B2
公开(公告)日:2020-08-18
申请号:US15134740
申请日:2016-04-21
申请人: Geron Corporation
IPC分类号: C12N15/10 , C12N15/113
摘要: Aspects of the disclosure include methods for the preparation of a polynucleotide. In some embodiments, the method includes contacting a first polynucleotide composition including: a polynucleotide having a sequence of 7 or more nucleoside subunits and at least two of the nucleoside subunits are joined by a N3′→P5′ thiophosphoramidate inter-subunit linkage; and non-target synthetic products and reagents; with a multivalent cation salt to precipitate a polynucleotide salt including at least one multivalent cation counterion; and separating the polynucleotide salt from the contacted first polynucleotide composition to produce a second polynucleotide composition including the polynucleotide salt. In certain embodiments, the method further includes contacting the polynucleotide salt with a reverse phase chromatography support; and eluting from the chromatography support a third polynucleotide composition including the polynucleotide. Also provided are compositions including a salt of the polynucleotide including at least one multivalent cation counterion.
-
公开(公告)号:US10738073B2
公开(公告)日:2020-08-11
申请号:US16024221
申请日:2018-06-29
申请人: Geron Corporation
摘要: Orthogonally protected 3′-amino nucleoside monomers and efficient methods for their synthesis are described. The methods employ selective protection of the 3′-amino group in the presence of the unprotected nucleoside base.
-
59.
公开(公告)号:US20200063214A1
公开(公告)日:2020-02-27
申请号:US16525026
申请日:2019-07-29
申请人: Geron Corporation
IPC分类号: C12Q1/6886 , G16H50/30 , G16B40/10 , C12Q1/6827 , A61K9/00 , G16H20/10 , A61K31/7105 , A61K47/54
摘要: This disclosure provides methods of identifying or selecting a patient most likely to benefit from treatment with a telomerase inhibitor, such as e.g. imetelstat, by testing a patient for: a lack of a mutation in each of JAK2, CALR, and MPL; and/or a high-molecular risk (HMR), based on the presence of a mutation in at least one of the following genes: ASXL1, EZH2, SRSF2, and IDH1/2. The patient may be suffering from myelofibrosis. The disclosure also provides methods of treating myelofibrosis, which include identifying such patients.
-
公开(公告)号:US10392418B2
公开(公告)日:2019-08-27
申请号:US15705019
申请日:2017-09-14
申请人: Geron Corporation
IPC分类号: C07H21/00 , C12N15/113 , C12P19/34
摘要: The present disclosure provides a solid phase method of making oligonucleotides via sequential coupling cycles including at least one coupling of a dinucleotide dimer subunit to a free 3′-terminal group of a growing chain. The oligonucleotides include at least two nucleoside subunits joined by a N3′→P5′ phosphoramidate linkage. The method may include the steps of (a) deprotecting the protected 3′ amino group of a terminal nucleoside attached to a solid phase support, said deprotecting forming a free 3′ amino group; (b) contacting the free 3′ amino group with a 3′-protected amino-dinucleotide-5′-phosphoramidite dimer in the presence of a nucleophilic catalyst to form an internucleoside N3′→P5′ phosphoramidite linkage; and (c) oxidizing (e.g., sulfurizing) the linkage. The compositions produced by the subject methods may include a reduced amount of one or more (N−x) oligonucleotide products. Also provided are pharmaceutical compositions including the subject oligonucleotide compositions.
-
-
-
-
-
-
-
-
-